EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Pi

Ensembl ID : ENSSBOG00000028102
Gene Symbol: GABRP
2 Cross references
124 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Theta

Ensembl ID : ENSSBOG00000020195
Gene Symbol: GABRQ
2 Cross references
87 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSSBOG00000022261
Gene Symbol: GABBR1
2 Cross references
264 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSSBOG00000035296
Gene Symbol: GABBR2
2 Cross references
241 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSSBOG00000023899
Gene Symbol: GIPR
2 Cross references
93 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glucagon Like Peptide 1 Receptor

Ensembl ID : ENSSBOG00000026131
Gene Symbol: GLP1R
2 Cross references
133 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSSBOG00000025968
Gene Symbol: GLP2R
2 Cross references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glucagon Receptor

Ensembl ID : ENSSBOG00000034949
Gene Symbol: GCGR
2 Cross references
183 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glucokinase

Ensembl ID : ENSSBOG00000000143
Gene Symbol: GCK
2 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glucosylceramidase Beta 1

Ensembl ID : ENSSBOG00000021424
Gene Symbol: GBA1
2 Cross references
252 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSSBOG00000035431
Gene Symbol: GRIA1
2 Cross references
323 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSSBOG00000021964
Gene Symbol: GRIA2
2 Cross references
320 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).